A serum metabolomics analysis reveals a panel of screening metabolic biomarkers for esophageal squamous cell carcinoma
Open Access
- 6 May 2021
- journal article
- letter
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (5), e419
- https://doi.org/10.1002/ctm2.419
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Serum Metabolomics for Biomarker Screening of Esophageal Squamous Cell Carcinoma and Esophageal Squamous Dysplasia Using Gas Chromatography-Mass SpectrometryACS Omega, 2020
- Untargeted Metabolomics Analysis of Esophageal Squamous Cell Carcinoma Discovers Dysregulated Metabolic Pathways and Potential Diagnostic BiomarkersJournal of Cancer, 2020
- 1H-NMR spectroscopy identifies potential biomarkers in serum metabolomic signatures for early stage esophageal squamous cell carcinomaPeerJ, 2019
- MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysisNucleic Acids Research, 2018
- Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and TherapyGastroenterology, 2018
- Screening and prevention strategies and endoscopic management of early esophageal cancerChinese Clinical Oncology, 2017
- Precision prevention of oesophageal adenocarcinomaNature Reviews Gastroenterology & Hepatology, 2015
- Endoscopic screening for esophageal squamous cell carcinoma.2013
- Value of endoscopic methylene blue and Lugol's iodine double staining and detection of GST-Π and telomerase in the early diagnosis of esophageal carcinomaWorld Journal of Gastroenterology, 2005
- The strategy for esophageal cancer control in high-risk areas of China.Japanese Journal of Clinical Oncology, 2002